Jack W. Schuler Buys 65,000 Shares of Accelerate Diagnostics, Inc. (AXDX) Stock

Accelerate Diagnostics, Inc. (NASDAQ:AXDX) Director Jack W. Schuler purchased 65,000 shares of Accelerate Diagnostics stock in a transaction dated Monday, May 14th. The shares were purchased at an average price of $19.97 per share, for a total transaction of $1,298,050.00. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website.

Shares of AXDX stock opened at $22.15 on Friday. Accelerate Diagnostics, Inc. has a one year low of $20.45 and a one year high of $21.25. The company has a current ratio of 27.80, a quick ratio of 26.44 and a debt-to-equity ratio of 0.65.

Accelerate Diagnostics (NASDAQ:AXDX) last announced its earnings results on Wednesday, May 9th. The medical research company reported ($0.27) EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.32) by $0.05. Accelerate Diagnostics had a negative return on equity of 51.23% and a negative net margin of 1,568.29%. The business had revenue of $0.80 million for the quarter, compared to analysts’ expectations of $2.64 million. equities research analysts predict that Accelerate Diagnostics, Inc. will post -1.38 earnings per share for the current year.

Several analysts have recently weighed in on the company. BidaskClub upgraded Accelerate Diagnostics from a “sell” rating to a “hold” rating in a report on Friday. Zacks Investment Research cut Accelerate Diagnostics from a “hold” rating to a “sell” rating in a report on Monday. BTIG Research restated a “hold” rating on shares of Accelerate Diagnostics in a report on Sunday, February 18th. Finally, ValuEngine cut Accelerate Diagnostics from a “hold” rating to a “sell” rating in a report on Friday, February 9th. Two investment analysts have rated the stock with a sell rating, two have issued a hold rating and one has issued a buy rating to the stock. The stock currently has a consensus rating of “Hold” and an average target price of $33.00.

A number of hedge funds have recently made changes to their positions in AXDX. Artal Group S.A. boosted its holdings in Accelerate Diagnostics by 150.0% in the fourth quarter. Artal Group S.A. now owns 500,000 shares of the medical research company’s stock valued at $13,100,000 after acquiring an additional 300,000 shares during the last quarter. Deutsche Bank AG boosted its holdings in shares of Accelerate Diagnostics by 1,236.9% during the 4th quarter. Deutsche Bank AG now owns 312,470 shares of the medical research company’s stock worth $8,185,000 after buying an additional 289,098 shares in the last quarter. Chicago Capital LLC bought a new position in shares of Accelerate Diagnostics during the 1st quarter worth approximately $6,593,000. Amundi Pioneer Asset Management Inc. bought a new position in shares of Accelerate Diagnostics during the 4th quarter worth approximately $5,311,000. Finally, Wells Fargo & Company MN boosted its holdings in shares of Accelerate Diagnostics by 326.3% during the 1st quarter. Wells Fargo & Company MN now owns 262,745 shares of the medical research company’s stock worth $6,004,000 after buying an additional 201,113 shares in the last quarter. Institutional investors and hedge funds own 45.33% of the company’s stock.

About Accelerate Diagnostics

Accelerate Diagnostics, Inc, an in vitro diagnostics company, provides solutions for the diagnosis of serious infections in the United States. It offers Accelerate Pheno system, an in vitro diagnostic platform for the identification and antibiotic susceptibility testing of pathogens associated with serious or health care-associated infections, including gram-positive and gram-negative organisms, as well as yeast.

Insider Buying and Selling by Quarter for Accelerate Diagnostics (NASDAQ:AXDX)

Receive News & Ratings for Accelerate Diagnostics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Accelerate Diagnostics and related companies with MarketBeat.com's FREE daily email newsletter.



Leave a Reply